

**Bereskin & Parr**

Barristers and Solicitors/Patent and Trade Mark Agents  
Practice Restricted to Intellectual Property Law

Micheline Gravelle B.Sc., M.Sc. (Immunology.)  
416 957 1682 mgravelle@bereskinparr.com

Your Reference: 09/442,143  
Our Reference: 9579-14

November 2, 2001

**By Facsimile****AFTER FINAL**

The Commissioner of Patent and Trademark  
Washington, D.C. 20231  
U.S.A.

Dear Sir:

Re: **RESPONSE**  
**United States Patent Application No. 09/442,143**  
**Filed: November 15, 1999**  
**Entitled: Methods of Modulating Immune Coagulation**  
**Inventors: Gary Levy and David A. Clark**  
**Examiner: P. Nolan**  
**Art Unit: 1644**

The present letter is filed in response to the office action dated September 24, 2001.  
This response is being filed within two months from the date of the final action.

Please amend the application as follows

**In the Specification:**

Please replace the paragraphs at page 5, line 4 to line 6 with the following rewritten paragraphs:

—Figure 6 is the amino acid sequence of the mouse (SEQ.ID.NO.4) and human (SEQ.ID.NO.2) Fgl2 proteins, with the 5 glycosylation sites underlined;

Figure 7 shows the predicted secondary structure of the hFgl2 protein (SEQ.ID.NO.2);—